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Hyperhomocysteinemia, a risk factor for cardiovascular disorder, obesity, and type 2 diabetes, is prevalent among Indians who
are at high risk of these metabolic disorders. We evaluated association of common variants of genes involved in homocysteine
metabolism or its levels with type 2 diabetes, obesity, and related traits in North Indians. We genotyped 90 variants in initial phase
(2.115 subjects) and replicated top signals in an independent sample set (2.085 subjects). The variant MTHFR-rs1801133 was the
top signal for association with type 2 diabetes (OR = 0.78 (95% CI = 0.67–0.92), P = 0.003) and was also associated with 2 h
postload plasma glucose (P = 0.04), high-density lipoprotein cholesterol (P = 0.004), and total cholesterol (P = 0.01) in control
subjects. These associations were neither replicated nor significant after meta-analysis. Studies involving a larger study population
and different ethnic groups are required before ruling out the role of these important candidate genes in type 2 diabetes, obesity,
and related traits.
1. Introduction
Homocysteine, a thiol containing amino acid, has emerged
as a determinant for many complex metabolic disorders in
the past few years. Hyperhomocysteinemia is a well-known
independent risk factor for cardiovascular diseases [1, 2]
and is also associated with diabetic complications [3–6],
obesity, [7, 8] and metabolic syndrome [9]. Hyperhomo-
cysteinemia may lead to any of the above metabolic disorders
by elicitation of oxidative stress [10], systemic inflammation,
[11] and/or endothelial dysfunction [12]. These factors are
known to promote insulin resistance and β-cell dysfunction,
two important underlying causes for type 2 diabetes [13].
Indians are at high risk for these metabolic disorders, as re-
flected by high prevalence of type 2 diabetes patients and
metabolic syndrome [14, 15]. The observed trend of hyper-
homocysteinemia among Indians [16] indicates the possi-
bility of aberrant homocysteine metabolism with increased
risk of metabolic disorders in Indian population. Hence, it
becomes important to examine the association of variants of
genes involved in homocysteine metabolism or modulating
plasma homocysteine level with type 2 diabetes and related
traits in Indians.
Previous studies suggested contribution of variants in
homocysteine metabolism pathway genes in susceptibility to
obesity, type 2 diabetes, or related traits [17–19]. Methylene
tetrahydrofolate reductase (MTHFR) is shown to act syn-
ergistically with angiotensin-I-converting enzyme (ACE) to
modulate type 2 diabetes risk [17]. The C677T polymor-
phism (rs1801133) of MTHFR is the most studied genetic
variation and is associated with hyperhomocysteinemia [20].
Many studies have also reported association of C677T
with type 2 diabetes and related complications [21–26].
Variants of MTHFR and other homocysteine metabolism
pathway genes like MTR and MTRR have also been shown
to be associated with obesity [27]. However, little insight
is available in this regard from limited reports showing
association of variants in homocysteine metabolism pathway
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genes with plasma homocysteine levels in Indians [28, 29].
Here, we assessed association of 90 SNPs in 18 genes, from
homocysteine metabolism pathway or those associated with
homocysteine levels, with type 2 diabetes, obesity, and related
traits in 4.200 North Indians.
2. Materials and Methods
2.1. Subjects. The study was performed in two phases: eval-
uation of 90 SNPs for association with type 2 diabetes and
related traits in the first phase and replication of top signal
in the second phase. All study participants were un-related,
urban dwellers of Indo-European ethnicity from North
India. All nondiabetic controls were recruited through “dia-
betes awareness camps” conducted in Delhi and National
Capital Region, while type 2 diabetes patients were recruited
from Endocrinology Clinic, All India Institute of Medical
Sciences, New Delhi. Study population for the first phase
consisted of 2,115 subjects comprising of 1.073 type 2 dia-
betes patients (from clinics) and 1.042 nondiabetic controls.
Replication phase comprised of an independent sample set
of 2.085 subjects including 1.047 type 2 diabetes patients and
1.308 nondiabetic controls. Subjects were characterized as
type 2 diabetes patients and controls based on inclusion and
exclusion criteria described previously [30]. Briefly, type 2
diabetes was defined by the WHO criteria [31], while criteria
for non-diabetic controls were as follows: age ≥40 years,
HbA1c < 6.0%, fasting plasma glucose <6.11mmol/L, and
no family history of diabetes.
Anthropometric and biochemical estimations were per-
formed as described earlier [30]. The measured variables
included height, weight, waist circumferences, hip circum-
ferences, systolic and diastolic blood pressure, body mass
index (BMI) and waist to hip ratio (WHR), glycosylated
haemoglobin 1c (HbA1c), fasting plasma glucose (FPG), 2h
postload plasma glucose (2h PPG), fasting plasma insulin
(FPI), C-reactive protein (CRP), C-peptide, total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low
density lipoprotein cholesterol (LDL-C), triglyceride (TG),
blood urea, and creatinine. Subjects with BMI < 23 kg/m2
were classified as normal weight (NW), whereas subjects
with BMI ≥ 23 kg/m2 were considered as overweight/obese
(OW/OB), according to WHO Expert Committee recom-
mendations for Asians [32]. Homeostasis model assessments
of insulin resistance (HOMA-IR), β-cell function (HOMA-
B), and insulin sensitivity (HOMA-S) were obtained using
formulae as reported previously [33, 34].
The study was approved by ethics committee of partici-
pating institutions and was conducted in accordance with the
principles of Helsinki Declaration.Written informed consent
was obtained from each study subject.
2.2. Genotyping. We selected 79 SNPs from 15 genes which
are involved in homocysteine metabolism pathway and 11
SNPs from 2 genes (NOS3 and ACE) reported to be associat-
ed with homocysteine levels [17, 35] (see Table 1 in Supple-
mentary Material available online at: 10.1155/2012/960318).
SNPs in functional regions, with minor allele frequency
(MAF) > 0.05, polymorphic in at least two populations
and tag SNPs were preferred. Genotyping in the first phase
was performed using Illumina Golden Gate assay. Stringent
quality control (QC) criteria were applied as provided pre-
viously [36]. Also, 7.2% (147 samples) of total samples were
genotyped in duplicate, and an error rate < 0.01 was figured.
Of the 78 QC passed SNPs, those with MAF < 0.05 (N = 9)
or deviating from Hardy-Weinberg equilibrium (HWE) in
control subjects (N = 2) (P < 6.41×10−4, 0.05/78) were also
excluded. Consequently, a total of 67 SNPs were considered
for further association analyses.
In replication phase, we genotyped the top signal of first
phase, rs1801133 (MTHFR), using iPLEX on a MassARRAY
System (Sequenom, San Deigo, Calif, USA). The average
genotyping success rate was 97% with >99.8% consistency
rate in genotype calls in 5% duplicates.
2.3. Statistical Analysis. Genotype distributions were ana-
lyzed for deviation from HWE using χ2 test. Association
of SNPs with type 2 diabetes and obesity was determined
by logistic regression assuming log additive model. Linear
regression was performed under log additive model for
association analysis of SNPs with quantitative traits in
control subjects. The analyses were adjusted for sex, age,
and BMI as appropriate. Odds ratios (ORs), β, and 95%
confidence intervals (CI,) were calculated with respect to
minor allele. To assess difference in allele frequency of
the two study populations, equality of proportions Z-test
was applied. Meta-analysis under fixed and random effect
models was done by merging summary statistics of two
phases. After correcting for multiple testing (Bonferroni
correction), a P value < 3.32 × 10−5 (α = 0.05/(58 ×
26)) was considered significant (58 independent SNPs and
26 traits). Power of study was calculated assuming 10%
disease risk at α = 0.05 under log additive model using
Quanto (http://hydra.usc.edu/gxe/). Statistical analyses were
performed using SPSS version 17.0 (SPSS, Chicago, Ill), Stata
10.1 (Stata Corporation, College Station, Tex, United States),
and PLINK (http://pngu.mgh.harvard.edu/purcell/plink/)
unless specified otherwise.
3. Results
Clinical characters of the study subjects (phase 1 and phase
2) are provided in Table 1. The study had >82.9% power
to detect association of variants with allele frequency of
0.20 and genetic effect size of 1.25. Allele frequency of
controls and cases of the initial and replication phase for
SNP rs1801133 did not differ significantly. The allelic and
genotypic distribution of SNPs for type 2 diabetes patients
and non-diabetic control subjects recruited in the first phase
are provided in Supplementary Table 1, whereas details
for normal weight (NW) and overweight/obese (OW/OB)
subjects are presented in Supplementary Table 2.
Association analysis results of all the SNPs with type
2 diabetes are presented in Supplementary Table 3.
MTHFR variant rs1801133 showed strongest association
with type 2 diabetes in initial phase (OR = 0.78 (95% CI
0.67–0.92), P = 0.003) (Table 2). However, this could not
be replicated in the second phase (OR = 1.01 (95% CI
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Table 1: Anthropometric and clinical characteristics of the study populations.
Characteristics
Phase 1 Phase 2
Type 2 diabetes patients Control Subjects Type 2 diabetes Patients Control Subjects
N (Men/Women) 1019 (592/427) 1006 (606/400) 1047 (619/428) 1038 (516/522)
Age (years) 53 (45–62) 50 (44–60) 55 (49–62) 54 (45–64)
BMI (Kg/m2)
Men 23.80 (22.00–26.00) 23.10 (20.10–5.70) 24.82 (22.68–27.76) 24.68 (22.35–27.39)
Women 26.70 (24.20–29.20) 25.00 (21.10–8.50) 27.39 (24.56–30.63) 26.37 (23.13–29.33)
WHR
Men 1.00 (0.97–1.03) 0.97 (0.92–1.0) 0.98 (0.95–1.03) 0.97 (0.93–1.01)
Women 1.00 (0.97–1.03) 0.86 (0.82–0.92) 0.93 (0.87–0.97) 0.86 (0.82–0.90)
Systolic BP (mmHg) 130 (130–140) 120 (112–132) 130 (122–140) 130 (120–140)
Diastolic BP (mmHg) 80 (78–90) 80 (70–88) 82 (80–90) 80 (78–90)
HbA1c (%) 7.80 (6.50–9.40) 5.20 (4.90–5.60) 8.20 (6.90–9.60) 5.65 (5.33–5.89)
FPG (mmol/L) 7.90 (6.40–10.30) 4.90 (4.50–5.30) 7.79 (6.21–10.27) 4.87 (4.43–5.27)
2h PPG (mmol/L) 5.57 (4.83–6.30) 5.63 (4.88–6.22)
FPI (pmol/L) 82.80 (42.0–166.80) 32.40 (17.40–57.60) 74.40 (26.00–96.00) 43.80 (28.20–63.60)
HOMA-IR 5.20 (2.30–9.60) 1.20 (0.60–2.00) 4.30 (2.30–9.30) 1.60 (1.00–2.40)
HOMA-B 60.25 (25.3–154.51) 73.40 (40.70–138.60) 61.66 (25.61–131.86) 105.27 (65.13–167.32)
HOMA-S 0.20 (0.10–0.46) 0.86 (0.49–1.69) 0.23 (0.11–0.44) 0.64 (0.42–1.03)
C-peptide (nmol/L) 0.89 (0.56–1.36) 0.53 (0.36–0.73) 1.05 (0.69–1.60) 0.66 (0.50–0.86)
CRP (mg/L) 2.20 (0.90–4.70) 1.30 (0.60–3.00) 1.86 (0.90–3.44) 1.61 (0.90–3.04)
TC (mmol/L) 4.20 (3.50–5.00) 4.40 (3.7–5.10) 4.64 (3.86–5.42) 4.91 (4.22–5.52)
LDL-C (mmol/L) 2.57 (1.99–3.36) 2.79 (2.33–3.41) 2.73 (2.10–3.42) 3.01 (2.49–3.51)
HDL-C (mmol/L) 1.03 (0.88–1.22) 1.06 (0.88–1.28) 1.11 (0.94–1.34) 1.24 (1.06–1.46)
TG (mmol/L) 1.60 (1.10–2.20) 1.30 (1.00–1.80) 1.43 (0.98–2.13) 1.22 (0.86–1.64)
Values provided are median (interquartile range).
N: number of individuals, BMI: body mass index, WHR: waist to hip ratio, BP: blood pressure, HbA1c: glycosylated haemoglobin 1c, FPG: fasting plasma
glucose, 2h PPG: 2h postload plasma glucose, FPI: fasting plasma insulin, HOMA-IR: homeostasis model assessments of insulin resistance, HOMA-B:
homeostasis model assessments for β-cell function, HOMA-S: homeostasis model assessments for insulin sensitivity, CRP: C-reactive protein, TC: total
cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein-cholesterol, TG: triglyceride.
0.87–1.19), P = 0.86). Meta-analysis also failed to detect
any association of rs1801133 with type 2 diabetes (P random
effect (Pr) = 0.38, P fixed effect (Pf ) = 0.05) (Table 3).
Our previous studies have indicated influence of obesity
status on association of genetic variants with type 2 diabetes
in North Indians [30, 37]. Thus, we stratified our subjects
into NW and OW/OB groups and assessed association with
type 2 diabetes in these subgroups. Among NW subjects,
we observed nominal association of MTHFR-rs1801133,
MTHFR-rs9651118, CHDH-rs4563403, CBS-rs706208, and
MTHFD1L-rs1555179 with type 2 diabetes (P value range=
0.002–0.04) (Table 2). On the other hand, in OW/OB in-
dividuals, MTHFD1-rs1076991 (OR = 0.81 (95% CI 0.69–
0.95) P = 0.01) and TCN2-rs1801198 (OR = 0.85 (95%
CI 0.72–0.99), P = 0.04) showed nominal association with
type 2 diabetes. In the second phase, association of MTHFR-
rs1801133 with type 2 diabetes in NW subjects could not be
replicated either in the second phase (P = 0.53) or upon
Meta-analysis (Pr/P f = 0.52/0.07) (Table 3).
Further, we investigated association of these SNPs with
obesity status (OW/OB versus NW) in non-diabetic con-
trol subjects (Supplementary Table 4). Only a nominal asso-
ciation of CHDH-rs4563403 (OR = 0.69 (95% CI 0.52–
0.92), P = 0.01), TCN2-rs1801198 (OR = 1.24 (95% CI
1.04–1.48), P = 0.02), and MTR-rs16834521 (OR = 0.82
(95% CI 0.68–0.99), P = 0.04) was observed in the first
phase (Table 2). The top signal MTHFR-rs1801133 was not
associated with obesity in both first and second phases or
after meta-analysis (Tables 2 and 3).
We also assessed association of variants with quantitative
traits related to type 2 diabetes and obesity. The first phase
control subjects showed only nominal association with the
quantitative traits as shown in Supplementary Table 5. Most
significant association was observed at AMD1-rs1007274
with LDL-C levels (β = −6.35 (95% CI (−9.61)–(−3.1)),
P = 1.41× 10−4). MTHFR variant rs1801133 was nominally
associated with 2h PPG (β = −5.06 (95% CI (−9.72)–
(−0.40)), P = 0.03), HDL-C (β = 2.14 (95% CI 0.68–
3.59), P = 0.004) and TC (β = 5.61 (95% CI 1.28–9.94),
P = 0.01) in the first phase (Table 3). In the second phase,
while none of the above associations were replicated, new
associations were observed with FPI (β = −0.77 (95% CI
−1.42–(−0.11)), P = 0.02), HOMA-IR (β = −0.20 (95% CI
−0.36–(−0.04)), P = 0.01), HOMA-B (β = −652.8 (95% CI
−1165–(−140.1)), P = 0.01) and HOMA-S (β = 0.62 (95%
CI 0.13–1.11), P = 0.01). Meta-analysis revealed association
of MTHFR-rs1801133 with LDL-C (Pr/P f = 0.02/0.02, Q =
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Table 2: Variants showing association (uncorrected P-value) with type 2 diabetes and obesity.
Trait Gene SNP
Allele
(major/minor)
MAF
(affected/unaffected)
OR (95% CI) P
Type 2 diabetes (total study population:
1019 cases versus 1006 controls)†
MTHFR rs1801133 C/T 0.18/0.21 0.78 (0.67–0.92) 0.003
Type 2 diabetes (Normal weight subjects:
290 cases versus 436 controls)†
MTHFR rs1801133 C/T 0.18/0.21 0.62 (0.46–0.85) 0.002
MTHFR rs9651118 C/T 0.26/0.25 1.31 (1.01–1.68) 0.04
CHDH rs4563403 G/A 0.10/0.11 0.66 (0.45–0.95) 0.02
CBS rs706208 T/C 0.41/0.39 1.30 (1.03–1.63) 0.03
MTHFD1L rs1555179 C/T 0.26/0.23 1.36 (1.04–1.78) 0.03
Type 2 diabetes (Obese/over-weight
subjects: 691cases versus 562 controls)†
MTHFD1 rs1076991 A/G 0.40/0.44 0.81 (0.69–0.95) 0.01
TCN2 rs1801198 G/C 0.42/0.44 0.85 (0.72–0.99) 0.04
Obesity (562 Obese/over-weight versus 436
normal weights)‡
CHDH rs4563403 G/A 0.09/0.13 0.69 (0.52–0.92) 0.01
TCN2 rs1801198 G/C 0.46/0.41 1.24 (1.04–1.48) 0.02
MTR rs16834521 T/C 0.31/0.35 0.82 (0.68–0.99) 0.04
†
Analyses adjusted for sex, age, and BMI. ‡Analysis performed only in control subjects and adjusted for sex and age, MAF: minor allele frequency, OR: odds
ratio, CI: confidence interval.
Table 3: Association of rs1801133 with all traits in initial phase, replication phase, and meta-analysis.
Trait
Initial phase Replication phase Meta-analysis
OR/β (95% CI) P OR/β (95% CI) P P f Pr OR f /β f ORr /βr Q I
Type2 diabetes (all)† 0.78 (0.67–0.92) 0.003 1.01 (0.87–1.19) 0.86 0.05 0.38 0.90 0.89 0.024 80.44
Type2 diabetes (NW)† 0.62 (0.46–0.85) 0.002 1.11(0.80–1.54) 0.53 0.07 0.52 0.81 0.83 0.012 84.30
Type2 diabetes (OW/OB)† 0.86 (0.71–1.04) 0.13 0.98 (0.82–1.17) 0.85 0.25 0.25 0.93 0.93 0.32 0.25
Obesity (NW versus OW/OB)‡ 1.07 (0.86–1.33) 0.56 1.11 (0.86–1.43) 0.42 0.33 0.33 1.09 1.09 0.82 0
BMI‡ 0.32 (−0.19–(−0.84)) 0.22 0.25 (−0.26–0.76) 0.34 0.12 0.12 0.29 0.29 0.84 0
Weight‡ 1.41 (0.02–2.80) 0.05 0.43 (−0.95–1.81) 0.54 0.07 0.07 0.92 0.92 0.33 0
WC‡ 0.47 (−0.76–1.70) 0.45 0.28 (−1.12–1.68) 0.70 0.41 0.41 0.39 0.39 0.84 0
WHR‡ −0.003 (−0.01–0.005) 0.46 −0.005 (−0.01–0.003) 0.24 0.18 0.18 −0.004 −0.004 0.73 0
FPG† 0.55 (−0.66–1.77) 0.37 -0.83 (−2.14–0.47) 0.21 0.84 0.86 −0.09 −0.12 0.13 56.98
2h PPG† −5.06 ((−9.72)–(−0.40)) 0.03 −1.13 (−4.84–2.58) 0.55 0.07 0.15 −2.65 −2.83 0.20 40.15
HbA1c† 0.02 (−0.03–0.07) 0.41 −0.03 (−0.07–0.01) 0.15 0.58 0.79 −0.009 −0.007 0.12 59.73
FPI† 0.43 (−0.44–1.30) 0.33 −0.77 ((−1.42)–(−0.11)) 0.02 0.21 0.73 −0.33 −0.20 0.03 78.49
HOMA-IR† 0.11 (−0.09–0.31) 0.30 −0.20 (−0.36–−0.04) 0.01 0.21 0.73 −0.08 −0.05 0.02 81.77
HOMA-B† 70.25 (−34.99–175.50) 0.19 −652.8 (−1165–−140.1) 0.01 0.44 0.49 41.02 −245.94 0.0068 86.36
HOMA-S† −0.09 (−0.26–0.07) 0.27 0.62 (0.13–1.11) 0.01 0.82 0.53 −0.02 0.23 0.0067 86.41
C-peptide† 0.01 (−0.10–0.12) 0.86 −0.07 (−0.17–0.04) 0.22 0.44 0.44 −0.03 −0.03 0.32 0
CRP† −0.16 (−0.38–0.05) 0.14 −0.12 (−0.34–0.1) 0.28 0.07 0.07 −0.14 −0.14 0.79 0
HDL-C† 2.14 (0.68–3.59) 0.004 −0.05 (−1.31–1.21) 0.94 0.07 0.36 0.89 1.01 0.03 79.83
LDL-C† 3.25 (−0.32–6.81) 0.07 2.61 (−1.03–6.26) 0.16 0.02 0.02 2.94 2.94 0.81 0
TC† 5.61 (1.28–9.94) 0.01 2.02 (−2.43–6.47) 0.37 0.01 0.03 3.86 3.85 0.26 22.03
TG† 7.08 (−0.88–15.05) 0.08 −3.73 (−10.26–2.81) 0.26 0.81 0.79 0.62 1.43 0.04 76.37
Systolic BP† 1.53 (−0.41–3.48) 0.12 −0.77 (−2.58–1.03) 0.40 0.66 0.76 0.29 0.35 0.09 65.50
Diastolic BP† 0.77 (−0.30–1.85) 0.16 −0.74 (−1.82–0.35) 0.18 0.95 0.98 0.02 0.02 0.05 73.47
Creatinine† 0.02 (−0.004–0.04) 0.11 −0.01 (−0.05–0.02) 0.50 0.33 0.68 0.01 0.01 0.16 50.00
Urea† 0.28 (−0.63–1.20) 0.54 −0.12 (−1.14–0.9) 0.82 0.76 0.76 0.10 0.10 0.57 0
Uric acid† 0.37 (−0.02–0.76) 0.06 0.05 (−0.1–0.19) 0.55 0.22 0.31 0.09 0.15 0.13 56.68
†
Analyses adjusted for sex, age, and BMI.
‡Analysis performed only in control subjects and adjusted for sex and age.
OR: odds ratio, CI: confidence interval, P f : P value for fixed effect, Pr : P value for random effect OR f : odds ratio for fixed effect, β f : beta value for fixed effect,
ORr : odds ratio for random effect, βr : beta value for random effect, Q: P value for Cochrane’s Q statistic, and I: I2 heterogeneity index (0–100).
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0.81, I2 = 0) and TC (Pr/P f = 0.01/0.03, Q = 0.26, I2 =
22.03). The association analysis results ofMTHFR-rs1801133
with all traits (dichotomous and continuous) in the initial
and replication phases and after meta-analysis are presented
in Table 3. However, none of the associations observed in the
present study were significant after correcting for multiple
testing.
4. Discussion
Homocysteine plays an important role in cell metabolism
as it is involved as an essential intermediate in the transfer
of activated methyl groups in the activated methyl cycle.
This cycle is responsible for global and gene promoter-
specific DNA methylation, an important factor in regulat-
ing gene expression [38–40]. The biological relevance of
homocysteine metabolism and its association with metabolic
disorders make it an important candidate pathway for type
2 diabetes. To the best of our knowledge, the present study
is first to comprehensively evaluate association of variants
of homocysteine metabolism pathway genes as well as genes
associated with homocysteine levels with type 2 diabetes,
obesity, and related traits.
The C677T (rs1801133) variant of MTHFR is an estab-
lished variant for plasma homocysteine levels [20, 41] and
has also been reported to be associated with type 2 diabetes,
its complications, and related traits like LDL-C levels [42,
43]. Association of MTHFR-rs1801133 with type 2 diabetes
in different population has been inconsistent [13, 17, 44].
The association studies of MTHFR-rs1801133 with type 2
diabetes and LDL-C levels have also been limited to studies
with small sample sizes. In the present study, MTHFR-
rs1801133 showed association with type 2 diabetes and
2h PPG, HDL-C, and TC in initial phase but could not
be replicated in the second phase. Interestingly, MTHFR-
rs1801133 showed nominal association with LDL-C levels in
meta-analysis as also suggested in a previous study though
this association was not significant after correcting for multi-
ple testing. The effect of MTHFR-rs1801133 variant on type
2 diabetes is most likely to be modulated by influencing levels
of homocysteine. However, in the absence of levels of homo-
cysteine in the present study population, this aspect could
not be probed.
We also observed association of other investigated vari-
ants with quantitative traits. Earlier reports have suggested
variants from MTR to be associated with obesity [27], similar
to this, we also observed variants of MTR (rs16834521) to
be associated with BMI. Variants from this gene were also
associated with TC (rs1805087 and rs10737812) and HbA1c
(rs1805087) levels. Interestingly, for the first time, we found
association of variant rs1007274 of AMD1 with plasma levels
of LDL-C, CRP and TC. Though these associations could not
reach the threshold after multiple testing corrections, they
provide important leads for follow-up studies in larger study
populations.
The present study is the largest among the studies
investigating association of MTHFR-rs1801133 and was
sufficiently powered to detect the previously reported effect
sizes. However, we were unable to confirm the associations
in Indian population. Differences in genetic architecture and
LD pattern due to ethnic differences [17, 21, 44] could be
one of the possible reasons for the observed inconsistency in
the association of MTHFR-rs1801133 with type 2 diabetes.
Previous studies by our group also observed inconsistency in
association of variants of TNF-LTA [45] and TNFRSF1B [46]
in Indians as compared to other ethnic groups indicating
difference in genetic structure.
Population stratification may also give rise to spurious
associations in a case-control study. However, cases and
controls in our study populations were recruited from geo-
graphical locations that form a homogenous cluster as
suggested by Indian genome variation consortium [47]. The
multidimensional scaling (MDS) plot drawn from the infor-
mation of 608 independent variants genotyped in the same
set of samples indicates genetic homogeneity of the samples
(Supplementary Figure 1). Study subjects of present study
are also a part of an ongoing genome-wide association study
of type 2 diabetes (unpublished data) and have been found to
belong to single cluster after performingMDS using genome-
wide SNP data. Hence, the subjects of two study populations
were genetically similar, but phenotypic difference in terms
of biochemical traits was observed between the two study
groups which could have influenced association results. It
is also known that dietary habits can influence levels of
homocysteine and in Indians; individuals with vegetarian
diet have been shown to have higher levels of homocysteine
[48]. We observe difference in the number of individuals on
vegetarian and nonvegetarian diets among both cases and
controls of phase1 and phase2 (Supplementary Table 6). We
believe this difference in status of vegetarian/nonvegetarian
diet would have led to the difference in the association
results of the two phases, but additional information on the
frequency and kind of non-vegetarian diet along with other
dietary information would have best answered this question.
5. Conclusions
In conclusion, variants from genes involved in homocysteine
metabolism showed suggestive evidence for association with
type 2 diabetes, obesity, and other related traits. However,
these associations were not confirmed upon replication.
Thus, studies involving a larger study population and dif-
ferent ethnic groups are required before completely ruling
out the role of these important candidate genes in type 2 dia-
betes, obesity, and related traits.
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